The Cottage Heart & Vascular Center’s structural heart team at Santa Barbara Cottage Hospital (SBCH) recently performed their ...

Abbott’s Amulet IDE trial put its left atrial appendage closure device up against the Watchman 2.5, which was approved by the ...

Click to share on Facebook (Opens in new window) Click to email a link to a friend (Opens in new window) Click to print (Opens in new window) Click to share on X (Opens in new window) The ...

Boston Scientific announced positive three-year primary endpoint results from a clinical trial of its Watchman FLX device.

Baystate Medical Center now offers this minimally invasive surgery where a left atrial appendage closure device is implanted into your heart. The WATCHMAN device closes off your LAA to keep blood ...

Boston Scientific Corporation BSX recently announced favorable three-year primary endpoint data from the OPTION global ...

The trial compared the stroke prevention device for left atrial appendage closure to blood thinners in people who underwent ...

(BSX) announced positive three-year primary endpoint results from the OPTION global clinical trial of the WATCHMAN FLX Left Atrirl Appendage Closure (LAAC) Device. The device demonstrated superior ...

The OPTION trial revealed non-inferior efficacy for all-cause death, stroke, or systemic embolism at 36 months. The WATCHMAN ...

Abbott (NYSE:ABT) announced new data supporting its Amplatzer Amulet left atrial appendage (LAA) occluder system.